Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 17, 2022 6:13pm
RE:RE:RE:Price Drop
My guess is you haven't watched the webinar today? Because that is by far the most relevant information. IMO, the primary menace for Algernon stock was Kulwant Malhi. It's said Algernon is now
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on Jan 17, 2022 4:06pm
RE:RE:Price Drop
OK! Let me try and explain with two caveats. 1. I am not knowledgeable about stock trading although I do watch it https://www.thecse.com/en/listings/life-sciences/algernon-pharmaceuticals 2.&
...more
Debt-Free and Thriving: Mining Company Reports 35% Revenue Growth in Q3 2024
posted Nov 12, 2024 9:00am by
Mandalay Resources Corp.
-
|
"Revenue growth and free cash flow generation reflect our cost controls and prudent capital management while benefitting from high metal prices. As of the end of Q3 our cash balance was a healthy $54.7 million – more than doubling since December 2023 – and we have fully repaid the $20 million outstanding balance on our revolving credit facility, strengthening our liquidity and financial flexibility ...read more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jan 17, 2022 12:32pm
Streetwise Reports:
This Pharmaceutical Company Has Brilliant Concept Biotechnology / Pharmaceuticals
(33)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Jan 17, 2022 11:15am
TODAY Mon Jan 17 4:15PM ET - Webinar w $AGN CEO Chris Moreau
Webinar - Algernon Pharma (AGN) w/ CEO Christopher Moreau Mon, Jan 17 at 4:15pm ET / 1:15pm PT Q&A with Radius Research Register Here - https://us02web.zoom.us/webinar/register
...more
(3213)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Jan 14, 2022 7:50pm
The Power Play by The Market Herald Releases Interview
(Sponsored) Algernon Pharmaceuticals (AGN) has received positive feedback from the U.S. FDA for investigation of NP-120 (Ifenprodil) for the treatment of chronic cough. Algernon filed an pre-IND
...more
(3)
•••
fruiscante1
X
View Profile
View Bullboard History
Comment by
fruiscante1
on Jan 14, 2022 2:20pm
RE:Price Drop
I get the impression that there's not enough eyes on this board these days for guessing games, would you mind just posting the information? (not trying to be a smart a$$ - I'm genuinely
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jan 14, 2022 12:42pm
Chronic Cough: Algernon versus Bellus Health versus Merck
Point Of Information: In regards to Algernon Pharmaceuticals Chronic Cough data, the CEO reported a 42% reduction in cough with no (0%) known taste disturbance. The CEO was being modest when he
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Jan 14, 2022 12:04pm
Price Drop
Price drops from 8.49 to 8.25 and guess who's involved?
(33)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Jan 13, 2022 7:35pm
Webinar w AGN CEO Christopher Moreau Mon Jan 17 @ 4:15PM ET
Webinar - Algernon Pharma (AGN) w/ CEO Christopher Moreau Mon, Jan 17 at 4:15pm ET / 1:15pm PT Q&A with Radius Research Register Here - https://us02web.zoom.us/webinar/register
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on Jan 13, 2022 12:28pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The Spirit Molecule (DMT)
Thank you. That chart raises the question of why is it that Algernon's market cap is low compared to its peers. today's trading shows the price as coming down and a company called Integral
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 12, 2022 4:14pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:The Spirit Molecule (DMT)
Follow up: Hopefully this "Peers" chart will stick this time. If not, just click on the "Peers" link above. it's all there.
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 12, 2022 4:10pm
RE:RE:RE:RE:RE:RE:RE:RE:The Spirit Molecule (DMT)
I agree the goal is to have multiple shots at goal. However, what I'm saying as an investor is we should not overshoot the runway with stacked up clinical trials that we thus far would need to
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on Jan 12, 2022 1:41pm
RE:RE:RE:RE:RE:RE:RE:The Spirit Molecule (DMT)
Perhaps I didn't explain myself very well. I am not advocating for Ifenprodil or suggesting that the company do anything different from what they are now doing. A stallholder knows that most of
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 12, 2022 12:37pm
RE:RE:RE:RE:RE:RE:The Spirit Molecule (DMT)
IMO, your list is upside down. The timeline and trend is now with DMT. We overshot the runway by more than a year with IPF and Chronic Cough is off the schedule for a standalone Phase 2 clinical trial
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on Jan 12, 2022 10:43am
RE:RE:RE:RE:RE:The Spirit Molecule (DMT)
As I understand it, Algernon was never intended to be a production company but one that will sell or license use of repurposed drugs. So It is setting out its stall and on that stall are; Ifenprodil
...more
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Meet the Top 5 Best Online Brokerages in Canada
Gold, growth and sustainability in focus for this resource company
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
Star Diamond Corporation Announces Third Quarter 2024 Results
Explained: The Psychology of Options Trading with Practical Tips
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.